Still, a body of evidence is gathering showing that individual AGEs have indeed potential as markers of diabetic complications, e.g., a methylglyoxal-derived hydroimidazolone-1 is proposed as an early marker of atherosclerosis in childhood diabetes [36], AGE4 (albumin modified by methylglyoxal) is an independent predictor of polyneuropathy in diabetes [35] and AGE1 (albumin modified by glucose) is significantly associated with lipid abnormalities in diabetes [37], justifying efforts put into developing epitope-specific immunoassays. Here, ALB is linked to polyneuropathy.